Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
uniQure (QURE) has shared an announcement.
uniQure N.V. has reached a significant milestone by administering the first dose in a Phase I/IIa clinical trial of AMT-191, their experimental treatment for Fabry disease. This progress may interest investors and those following biotech advancements, highlighting the company’s ongoing efforts to combat this genetic disorder.
Learn more about QURE stock on TipRanks’ Stock Analysis page.
